Cryptococcosis and sarcoidosis: Strange bed-fellows. A report of five cases

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 21, Issue 1, 2004, Pages 71-76

  Riha, Renata L ^a   Allen, Roger K A ^b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b St Andrews War Memorial Hospital   (Australia)

Author keywords

Cryptococcosis; Sarcoidosis

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; CORTICOSTEROID; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; SALBUTAMOL; STEROID;

ADULT; AUSTRALIA; BRAIN ABSCESS; BRONCHUS BIOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG RESPONSE; FEMALE; GRANULOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFECTION RISK; MALE; NOCARDIOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SARCOIDOSIS; SKIN BIOPSY; SYMPTOM; TRANSBRONCHIAL BIOPSY;

ADULT; ANTIFUNGAL AGENTS; BIOPSY; CRYPTOCOCCOSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 2042508994     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Cox LB, Tolhurst JC: Human Torulosis. (Melbourne University Press, Melbourne; 1946).
2. Diamond RD, Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Disease. (Churchill Livingstone; Philadelphia 2000).
3. Sadikot RT, Dore P, Arnold AG: Sarcoidosis and opportunistic infections. South Med J 2001; 94: 75-7.
4. Botha RJ, Wessels E: Cryptococcal meningitis in an HIV negative patient with systemic sarcoidosis. J Clin Pathol 1999; 52: 928-30.
5. Lauerma AI, Jeskanen L, Rantanen T, Stubb S, Kariniemi AL: Cryptococcosis during systemic glucocorticosteroid treatment. Dermatology 1999; 199: 180-2.
6. Bohne T, Sander A, Pfister-Wartha A, Schopf E: Primary cutaneous cryptococcosis following trauma of the right forearm. Mycoses 1996; 39: 457-9.
7. Hummel H, Stosiek P, Lindner R, Bar W: Osteomyelitis from Cryptococcus neoformans. Mycoses 1996: 39: 94-6.
8. Shijubo N, Fujishima T, Ooashi K, et al: Pulmonary cryptococcal infection in an untreated patient with sarcoidosis. Sarcoidosis 1995; 12: 71-4.
9. Ahmad I, Sharma OP: Sarcoidosis, cysticercosis and cryptococcosis: an unusual association. Sarcoidosis 1989; 6: 57-9.
10. Allen KS, Glickstein M, Arger PH. Bilaniuk L, Levy DW: Cryptococcosis associated with sarcoidosis: CT and MR findings. J Comput Assist Tomogr 1988; 2: 420-2.
11. Blanc M, Leuenberger P, Favez G: Invasive isolated pulmonary cryptococcosis. Case Report. Schweiz Med Wochenschr 1982; 112: 421-4.
12. Shaff MI, Berger JL, Green NE: Cryptococcal osteomyelitis, pulmonary sarcoidosis and tuberculosis in a single patient. South MedJ 1982; 75: 225-6.
13. Blanchon F, Vannier R, Brunel D, et al: Cutaneous, subcutaneous and lymph node cryptococcosis in a patient with sarcoidosis. Ann Med Interne 1979; 130: 455-8.
14. Aberg JA Mundy LM, Powderly WG: Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115: 734-40.
15. Kerkering TM, Duma RJ, Shadomy S: The evolution of pulmonary cryptococcosis. Ann Intern Med 1981; 94: 611-16.
16. Hammerman KJ, Powell KE Christianson CS, et al: Pulmonary cryptococcosis: clinical forms and treatment. Am Rev Resp Dis 1973; 108: 1116-23.
17. Riha RL, Slaughter RE, Zimmerman PV, Oliver WAS: Pulmonary cryptococcosis in an HIV-negative population. Am J Resp Crit Care Med 1999; 159: A 560.
18. Almeida GM, Andrade RM, Bento CA: The capsular polysaccharides of cryptococcus neoformans activate normal CD4 (+) T cells in a dominant Th2 pattern. J Immunol 2001; 167: 5845-51.
19. Aguirre K, Havell EA, Gibson GW, Johnson LL: Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 1995; 63: 1725-31.
20. Buchanan KL, Murphy JW: What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 1988; 4: 71-83.
21. Hunninghake GW, Costabel U, Ando M, et al: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
22. De Bosscher K, Vanden Berghe W, Haegeman G: Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22.
23. Winterbauer RH, Kraemer KG: The infectious complications of sarcoidosis: a current perspective. Arch Intern Med 1976; 136: 1356-62.
24. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A: Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun 2000; 68: 832-8.
25. Gadebusch HH, Gikas PW: The effect of cortisone upon experimental pulmonary cryptococcosis. Am Rev Resp Dis 1965; 92: 64-74.
26. Chen L, Goldman DL, Doering TL, Pirofski L-A, Casadevall A: The antibody response to Cryptococcus neoformans proteins and humans. Infect Immun 1999; 67: 2218-24.
27. Planck A, Katchar K, Eklund A, Gripenback S, Grunewald J: T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diff Lung Dis 2003; 20: 110-17.
28. Roebuck DJ, Fisher DA, Currie BJ: Cryptococcosis in HIV negative patients: findings on chest radiography. Thorax 1998; 53: 554-7.
29. Zinck SE, Leung AN, Frost M, Berry GJ, Muller NL: Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr 2002; 26: 330-4.
30. Saag MS, Graybill RJ, Larsen RA, et al: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-18.
31. Hoesley C, Dismukes WE: Overview of oral azole drugs as systemic antifungal therapy. Semin Resp Crit Care Med 1997; 18: 301-7.